Start Date
August 11, 2023
Primary Completion Date
December 31, 2026
Study Completion Date
June 30, 2027
Durvalumab
Subjects will receive durvalumab 1500mg IV every four weeks for four cycles, undergo assessment for residual disease, then a subset of subjects will receive an additional eight cycles of durvalumab.
Stereotactic Body Radiotherapy
Subjects will receive stereotactic radiation therapy concurrent with cycle 2 of durvalumab to a dose of 48Gy in four fractions. Fractionation may be modified for central tumors.
Circulating Tumor DNA assay
After four cycles of durvalumab, subjects will be evaluated at the MRD Landmark for residual ctDNA to determine subsequent treatment assignment.
BC Cancer--Kelowna, Kelowna
BC Cancer--Surrey, Surrey
BC Cancer--Vancouver, Vancouver
BC Cancer--Victoria, Victoria
Juravinski Cancer Centre, Hamilton
Collaborators (2)
AstraZeneca
INDUSTRY
Ozmosis Research Inc.
INDUSTRY
University of British Columbia
OTHER